Overview
My primary research interest has focused on on novel therapeutics, biomarkers and clinical trial development for ovarian and endometrial cancer. My fundamental goal is to develop a strong translational research program at Duke University in the Gynecologic Oncology Division, where knowledge we glean from our basic science research can be incorporated into our clinical trial program. Specifically, my focus is on biologic therapy and molecular biomarkers to direct therapy in patients with ovarian and endometrial cancers to determine if a strategy that incorporates both clinical and genomic information can improve clinical outcome, minimize unnecessary toxicity, and impact positively on quality of life.
In addition I am interested in robotic-assisted laparoscopic surgery for women with endometrial, ovarian and cervical cancers, as well as for benign gynecologic conditions.
Current Appointments & Affiliations
Recent Publications
Advancing physician-scientist career development in obstetrics and gynecology: 40 years of the American Association of Obstetricians and Gynecologists Foundation scholar program.
Journal Article Am J Obstet Gynecol · December 2025 Full text Link to item CiteMolecular Characterization and Clinical Implications of Endometrial Cancer.
Journal Article Obstet Gynecol · November 1, 2025 The classification of endometrial cancer (EC) has diverged from traditional histologic features based on microscopic appearance to objective molecular characterization. Molecular characterization of EC is pivotal to inform prognosis and to guide therapeuti ... Full text Link to item CiteA PHASE 3, OPEN-LABEL RANDOMIZED TRIAL TO COMPARE RINATABART SESUTECAN VERSUS INVESTIGATOR'S CHOICE OF CHEMOTHERAPY IN PATIENTS WITH PLATINUM-RESISTANT OVARIAN CANCER: RAINFOLâ„¢-02 (ENGOT-OV86/GOG-3107)
Conference International Journal of Gynecological Cancer · November 2025 Full text CiteRecent Grants
A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigator's Choice (IC) in Patients with Endometrial Cancer After Platinum-Based Chemotherapy and PD(L)-1 Therapy
Clinical TrialPrincipal Investigator · Awarded by Genmab A/S · 2026 - 2031A Phase I/II Randomized Multi-Cohort Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 in Combination with Anti-Cancer Agents in Participants with Advanced Solid Tumors
Clinical TrialPrincipal Investigator · Awarded by GlaxoSmithKline LLC · 2025 - 2030A Phase 3 Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of Sacituzumab Tirumotecan in Combination with Pembrolizumab Versus Pembrolizumab Alone as First-line Maintenance Treatment in Participants with Mismatch Repair Pr
Clinical TrialPrincipal Investigator · Awarded by Merck Sharp & Dohme · 2025 - 2030View All Grants